Nicotinic acetylcholine receptor alpha-6-beta-2 subtype (nAChR alpha6beta2*) (nAChR alpha6beta2*)

Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels that mediate fast excitatory neurotransmission in the central and peripheral nervous systems. The alpha6beta2* and beta2-containing subtypes are highly localized in the mesolimbic dopamine system, particularly on the terminals of dopaminergic neurons in the nucleus accumbens and cell bodies in the ventral tegmental area (VTA) (Gotti et al., 2010, PMID: 20130184). These specific subtypes play a critical role in regulating dopamine release, which is central to the rewarding effects of nicotine and other drugs of abuse (Exley et al., 2008, PMID: 18204445). Dysregulation of these receptors is implicated in nicotine addiction, Parkinson's disease, and various neuropsychiatric disorders (Quik et al., 2011, PMID: 21429113). Pharmacological targeting of alpha6beta2* receptors with partial agonists like varenicline or selective antagonists aims to reduce nicotine craving and withdrawal symptoms while minimizing side effects associated with broader nAChR activation (Tapper et al., 2004, PMID: 15528449). Consequently, these receptors are primary targets for smoking cessation therapies and are being investigated for neuroprotective roles in dopaminergic systems.

Other names

Alpha-6-beta-2 nicotinic acetylcholine receptorAlpha6-containing nicotinic receptorsCHRNA6-CHRNB2 receptor complexMesolimbic beta2-containing nAChRsAlpha6beta2beta3 nicotinic receptor

Partial agonism or antagonism of the alpha6beta2* and beta2-containing nicotinic receptors to modulate dopamine release in the mesolimbic pathway, thereby reducing the reinforcing effects of nicotine and alleviating withdrawal symptoms (Crunelle et al., 2010, PMID: 20550487; Gotti et al., 2010, PMID: 20130184).